Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Vyant Bio, Inc. (CGIX)
|
Add to portfolio |
|
|
|
| Price: |
$1.39
| | Metrics |
| OS: |
6.27
|
M
| |
-160
|
% ROE
|
| Market cap: |
$8.71
|
M
| |
-1055
|
% ROIC
|
|
Net cash:
|
$9.98
|
M
| |
$1.59
|
per share
|
|
EV:
|
|
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($15.4)
|
M
| |
|
|
|
EBIT
|
($15.9)
|
M
| |
|
|
| EPS |
($1.18)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 0.7 | 1.1 | 0.9 | 7.3 | 4.9 | 29.1 | 27.0 | 18.0 |
| Revenue growth | -42.0% | 32.4% | -88.1% | 48.1% | -83.1% | 7.7% | 49.9% | 76.9% |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 3.7 | 3.1 | 18.1 | 17.1 | 14.1 |
| Gross profit | 0.7 | 1.1 | 0.9 | 3.6 | 1.8 | 11.1 | 9.9 | 3.9 |
| Gross margin | 100.0% | 100.0% | 100.0% | 49.3% | 37.3% | 37.9% | 36.8% | 21.9% |
| Sales and marketing | 8.8 | 8.4 | 2.7 | 1.1 | 1.2 | 5.0 | 4.7 | 5.3 |
| Research and development | 6.8 | 4.3 | 3.2 | | 0.2 | 4.8 | 6.0 | 5.5 |
| General and administrative | | | | 5.2 | 6.7 | 19.9 | 16.0 | 14.6 |
| EBITA | -15.9 | -12.7 | -5.5 | -2.3 | -5.7 | -18.3 | -16.4 | -21.2 |
| EBITA margin | -2389.2% | -1104.8% | -630.9% | -30.9% | -116.3% | -62.7% | -60.6% | -117.6% |
| Amortization of intangibles | | 0.7 | 0.7 | 0.5 | 0.5 | 0.4 | 0.3 | 0.2 |
| EBIT | -15.9 | -13.4 | -6.2 | -2.7 | -6.2 | -18.6 | -16.7 | -21.4 |
| EBIT margin | -2389.2% | -1166.9% | -713.1% | -37.1% | -126.2% | -63.9% | -61.8% | -118.5% |
| Pre-tax income | -15.8 | -18.6 | -8.7 | -7.4 | -4.2 | -23.0 | -15.8 | -21.4 |
| Income taxes | 6.9 | 22.3 | 0.0 | -0.5 | 0.0 | -2.1 | 0.0 | -1.2 |
| Tax rate | | | 0.0% | 6.9% | 0.0% | 9.1% | 0.0% | 5.5% |
| Earnings from continuing ops | -8.9 | 3.7 | -8.7 | -6.9 | -4.2 | -20.9 | -15.8 | -20.2 |
| Earnings from discontinued ops | -6.9 | -22.3 | | | | | | |
| Net income | -15.8 | -18.6 | -8.7 | -6.7 | -20.4 | -20.9 | -15.8 | -20.2 |
| Net margin | -2373.4% | -1618.0% | -997.7% | -91.8% | -413.1% | -71.7% | -58.4% | -111.9% |
| |
| Diluted EPS | ($1.52) | $0.82 | ($3.48) | ($3.57) | ($4.62) | ($1.01) | ($1.00) | ($1.96) |
| Shares outstanding (diluted) | 5.9 | 4.5 | 2.5 | 1.9 | 0.9 | 20.7 | 15.9 | 10.3 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|